Welcome to our dedicated page for Medicenna Therapeutics news (Ticker: MDNA), a resource for investors and traders seeking the latest updates and insights on Medicenna Therapeutics stock.
Medicenna Therapeutics (MDNA) is a clinical-stage immunotherapy company at the forefront of developing novel and highly selective versions of IL-2, IL-4, and IL-13 superkines and first-in-class Empowered Cytokines (ECs). With a mission to lead in the development and commercialization of targeted ECs and superkines, Medicenna aims to revolutionize treatment for a broad range of cancers and immune-mediated diseases. The company leverages its expertise and collaborates with world-class researchers to create unique superkines.
Medicenna's innovative approach allows these superkines to function either as standalone short or long-acting therapeutics or to be fused with pro-apoptotic proteins. This fusion precisely delivers potent cell-killing agents to cancer cells, the immunosuppressive tumor micro-environment, and cancer stem cells, sparing healthy cells from harm. Additionally, these superkines can be fused with antibodies to create novel 'immunocytokines' or combined with other treatment modalities.
Currently, Medicenna is engaged in various promising projects. A notable recent achievement includes the characterization of its tumor-targeting and activatable T-MASK platform, designed to enhance tumor accumulation and tolerability of potent immune modulators. This innovation was presented at a significant conference on November 3, 2023.
As Medicenna continues to advance its pipeline of targeted treatments, it remains committed to transforming the therapeutic landscape for cancer and immune-related conditions. The company's financial health is supported by strategic partnerships and a focus on groundbreaking research and development.
Medicenna Therapeutics Corp. (NASDAQ: MDNA TSX: MDNA) announced that Dr. Fahar Merchant will present at the 10th Annual Leerink Global Healthcare Conference on February 26, 2021, at 3:00 PM ET. Investors can access a live webcast on Medicenna's Investor Relations website. Medicenna focuses on developing novel immunotherapies, including MDNA11, a long-acting IL2 Superkine, and MDNA55, which has completed a Phase 2b trial for rGBM, a deadly brain cancer. MDNA55 has received Fast-Track and Orphan Drug designation from the FDA.
Medicenna Therapeutics Corp. (MDNA) reported financial results for Q4 2020, highlighting key regulatory milestones in its pipeline. The FDA approved a novel hybrid trial design for MDNA55 in recurrent glioblastoma, reducing costs and timelines. Additionally, positive feedback from the UK’s MHRA supports the Phase 1/2 trial of MDNA11, with initiation expected in mid-2021. The company experienced a net loss of $5.3 million, up from $2.4 million a year earlier, primarily due to increased R&D expenses. Medicenna had cash reserves of $33.2 million, sufficient to fund operations through late 2022.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) reported financial results for the quarter ended December 31, 2020, showing a net loss of $5.3 million, or $0.11 per share, compared to a loss of $2.4 million, or $0.07 per share in the same quarter of 2019. Key highlights include FDA acceptance of the hybrid trial design for MDNA55 in recurrent glioblastoma and positive feedback from the UK’s MHRA for the MDNA11 Phase 1/2 trial. The company had cash and equivalents of $33.2 million, with additional funds received post-quarter amounting to approximately $7.8 million.
Medicenna Therapeutics Corp. (NASDAQ: MDNA) announced a sales agreement with SVB Leerink to offer up to US$25 million in common shares through at-the-market offerings on the Nasdaq. The ATM Offering will not occur in Canada or via the Toronto Stock Exchange. Proceeds from the offering will be allocated to general corporate purposes, including research and development and clinical trials. The offering will end once the maximum amount is raised, the agreement is terminated, or by August 28, 2022.
Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced an oral presentation at the 2nd Annual Glioblastoma Drug Development Summit on December 9, 2020. Dr. Fahar Merchant, CEO, will present updated Phase 2b trial data for MDNA55, targeting recurrent glioblastoma (rGBM), and outline a planned Phase 3 registration trial. The FDA has approved an innovative trial design to use matched external control, potentially expediting timelines and lowering costs. The presentation is part of a broader effort to advance MDNA55 as an effective treatment for rGBM.
Medicenna Therapeutics Corp. (NASDAQ: MDNA TSX: MDNA) will host a key opinion leader (KOL) call on December 11, 2020, at 11:00 AM ET regarding MDNA55, a treatment for recurrent glioblastoma multiforme.
The call will feature experts, including Dr. David Reardon from Harvard Medical School and Dr. John Sampson from Duke School of Medicine, discussing current treatment landscapes and unmet needs in rGBM. They will also address Medicenna's regulatory plans for MDNA55 following the presentations.
Medicenna Therapeutics Corp. (NASDAQ: MDNA) announced that CEO Fahar Merchant will participate in fireside chats and virtual investor meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference and Evercore ISI 3rd Annual HealthCONx Conference. A pre-recorded chat will be available until December 3. Dr. Merchant's live chat is scheduled for December 1 at 4:45 PM ET. Medicenna focuses on immunotherapy, notably developing MDNA11 and MDNA55, both aimed at treating various cancers. MDNA11 is set for clinical readiness in 2021.
Medicenna Therapeutics Corp. (NASDAQ: MDNA) announced participation in the 2020 Society for Neuro-Oncology Annual Meeting, offering two on-demand oral presentations. The presentations will discuss findings from the MDNA55-05 Phase 2b trial for recurrent glioblastoma multiforme (rGBM). Following a successful End of Phase 2 Meeting, the FDA has approved an innovative Phase 3 trial design allowing two-thirds of subjects from an external control arm, potentially reducing timelines and costs. Presentations are available online starting November 19, 2020.
Medicenna Therapeutics Corp. (NASDAQ: MDNA) reported its Q3 financial results for 2020, showing a net loss of $3.8 million, up from $1.9 million in the same quarter last year. The increase in loss is attributed to higher R&D expenditures and costs related to its Nasdaq listing. Clinical developments include a favorable FDA agreement for a hybrid registration trial for MDNA55 targeting recurrent glioblastoma, with notable survival benefits observed in recent studies. The company has $34.2 million in cash to support operations until mid-2022 and is advancing its MDNA11 program.
Medicenna Therapeutics Corp. (Nasdaq: MDNA) announced that CEO Fahar Merchant will present at two significant events this November 2020. The Next-Gen Cytokine Therapeutics Summit will feature a presentation on “Designer Superkines” on November 3 at 9:50 am ET. Additionally, the Stifel 2020 Virtual Healthcare Conference will take place on November 16 at 4:40 pm ET, along with SVB Leerink Oncology 1x1 Day on November 19. A live webcast of the Stifel presentation will be available on Medicenna's investor relations page.
FAQ
What does Medicenna Therapeutics specialize in?
What are superkines?
How does Medicenna's T-MASK platform work?
What are empowered cytokines (ECs)?
What recent achievements has Medicenna made?
What is the company's mission?
How does Medicenna ensure the safety of its treatments?
What are immunocytokines?
How does Medicenna collaborate with other researchers?
What is the financial outlook for Medicenna?
